Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Pacira BioSciences Inc.

    NASDAQ: PCRX · Real-Time Price · USD
    25.83
    -0.10 (-0.39%)
    At close: May 30, 2025, 3:59 PM
    25.75
    -0.31%
    After-hours: May 30, 2025, 05:04 PM EDT
    -0.39%
    Bid 18.1
    Market Cap 1.2B
    Revenue (ttm) 702.77M
    Net Income (ttm) -103.73M
    EPS (ttm) -2.27
    PE Ratio (ttm) -11.38
    Forward PE 7.56
    Analyst Buy
    Ask 29.19
    Volume 448,243
    Avg. Volume (20D) 933,219
    Open 25.93
    Previous Close 25.93
    Day's Range 25.36 - 25.99
    52-Week Range 11.16 - 31.64
    Beta 0.56

    About PCRX

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol PCRX
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for PCRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +14.67%
    Pacira BioSciences shares are trading higher after... Unlock content with Pro Subscription
    1 month ago
    -0.82%
    Pacira BioSciences shares are trading higher after the company announced settlement of litigation related to EXPAREL patents.
    news image

    6 days ago · accessnewswire.com

    Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pacira BioSciences, Inc. (PCRX) And Encourages Investors to Reach Out

    NEW YORK CITY, NY / ACCESS Newswire / May 25, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company"...

    news image

    1 week ago · accessnewswire.com

    Bronstein, Gewirtz & Grossman, LLC Encourages Pacira BioSciences, Inc. (PCRA) Shareholders to Inquire about Securities Investigation

    NEW YORK CITY, NY / ACCESS Newswire / May 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company"...

    news image

    2 weeks ago · accessnewswire.com

    Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pacira BioSciences, Inc. (PCRA) and Encourages Investors to Learn More About the Investigation

    NEW YORK CITY, NY / ACCESS Newswire / May 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Company"...

    news image

    3 weeks ago · zacks.com

    Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates

    PCRX reports mixed first-quarter results, wherein earnings beat estimates but revenues miss the same. Exparel sales witness weak year-over-year growth.

    news image

    3 weeks ago · seekingalpha.com

    Pacira BioSciences, Inc. (PCRX) Q1 2025 Earnings Call Transcript

    Pacira BioSciences, Inc. (NASDAQ:PCRX ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Susan Mesco - Head of Investor Relations Frank Lee - Chief Executive Officer Jonath...

    news image

    3 weeks ago · zacks.com

    Pacira (PCRX) Q1 Earnings Surpass Estimates

    Pacira (PCRX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.62 per share a year ago.

    news image

    3 weeks ago · zacks.com

    5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates

    Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.

    news image

    1 month ago · zacks.com

    Why Pacira (PCRX) is Poised to Beat Earnings Estimates Again

    Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

    news image

    1 month ago · accessnewswire.com

    Pacira BioSciences, Inc. (PCRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

    NEW YORK CITY, NY / ACCESS Newswire / April 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pacira BioSciences, Inc. ("Pacira" or "the Compan...

    news image

    1 month ago · seekingalpha.com

    Pacira BioSciences Remains A 'Buy' For Pain Management With The NOPAIN Act

    PCRX focuses on non-opioid pain management with Exparel, Zilretta, and iovera, delivering targeted pain relief with fewer side effects. A key secular tailwind for them comes from the NOPAIN Act, which...

    Add to Watchlist